| Title |
Statin Therapy in Metabolic Syndrome and Hypertension Post-JUPITER: What is the Value of CRP?
|
|---|---|
| Published in |
Current Atherosclerosis Reports, November 2010
|
| DOI | 10.1007/s11883-010-0143-2 |
| Pubmed ID | |
| Authors |
Sridevi Devaraj, David Siegel, Ishwarlal Jialal |
| Abstract |
Much evidence supports a pivotal role for inflammation in atherosclerosis. C-reactive protein (CRP), the prototypic marker of inflammation in humans, is a cardiovascular risk marker and may also promote atherogenesis. CRP levels are increased in metabolic syndrome and hypertension and confer increased risk of cardiovascular events in patients in these subgroups. Statins have been shown to lower low-density lipoproteins and CRP independently, and reduce cardiovascular events in subjects with and without metabolic syndrome and hypertension. In this review, we focus on the results from the primary prevention statin trial, Justification for the Use of statins in Primary prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER), which showed reductions in LDL, CRP, and cardiovascular events. Post-JUPITER, the new guidelines will now need to consider recommending high-sensitivity CRP testing to intermediate-risk metabolic syndrome patients and those with hypertension and intermediate risk so that we can better identify candidates at greater risk and reduce cardiovascular burden in these subjects with statin therapy. |
Mendeley readers
The data shown below were compiled from readership statistics for 64 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Indonesia | 1 | 2% |
| Canada | 1 | 2% |
| Unknown | 62 | 97% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Bachelor | 11 | 17% |
| Student > Master | 10 | 16% |
| Student > Ph. D. Student | 7 | 11% |
| Researcher | 5 | 8% |
| Student > Postgraduate | 5 | 8% |
| Other | 14 | 22% |
| Unknown | 12 | 19% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 27 | 42% |
| Pharmacology, Toxicology and Pharmaceutical Science | 7 | 11% |
| Agricultural and Biological Sciences | 6 | 9% |
| Nursing and Health Professions | 3 | 5% |
| Biochemistry, Genetics and Molecular Biology | 2 | 3% |
| Other | 4 | 6% |
| Unknown | 15 | 23% |
Attention Score in Context
This research output has an Altmetric Attention Score of 3. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 13 January 2016.
All research outputs
#8,882,501
of 26,017,215 outputs
Outputs from Current Atherosclerosis Reports
#421
of 884 outputs
Outputs of similar age
#42,592
of 114,567 outputs
Outputs of similar age from Current Atherosclerosis Reports
#2
of 4 outputs
Altmetric has tracked 26,017,215 research outputs across all sources so far. This one is in the 42nd percentile – i.e., 42% of other outputs scored the same or lower than it.
So far Altmetric has tracked 884 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 14.3. This one is in the 38th percentile – i.e., 38% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 114,567 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 22nd percentile – i.e., 22% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 4 others from the same source and published within six weeks on either side of this one. This one has scored higher than 2 of them.